Maiden Dividend And Royalties
Neuren Pharmaceuticals Announces Maiden Interim Dividend Following Strong DAYBUE Royalties Growth
Anonymous
Key Points
1
Neuren’s royalties for full-year 2026 are forecast to be US$53–56 million, with a potential US$35 million milestone in Europe following the first commercial sale.
2
The European Commission granted DAYBUE marketing authorisation for Rett syndrome across all 27 EU member states, Iceland, Liechtenstein and Norway on 24 August 2026, with Germany expected to launch in early Q4 2026.
3
NNZ-2591 (ercanetide) Koala Phase 3 study update: 15 sites across the US and Canada are enrolling, eight sites activated for the open-label extension, and Neuren is pursuing a Type B End of Phase 2 meeting with the US FDA for Pitt Hopkins syndrome.
4
DAYBUE STIX uptake continues to advance, with 40% of all US DAYBUE patients on STIX by 30 June 2026 and about 45% of Q2 STIX demand from new or returning patients.
5
Neuren’s first interim dividend details: ex-dividend date 15 September 2026, record date 16 September 2026, and payment date 7 October 2026; the payout will be fully franked to the extent credits permit.
Neuren Pharmaceuticals declared its first-ever fully franked dividend of 15 cents per share, backed by surging royalties from DAYBUE — its rare-disease blockbuster. Market Screener reported H1 2026 royalty income hit US$23.3 million, even as DAYBUE net sales climbed 25% to US$226 million on momentum in the US and uptake of the STIX formulation.
The biotech company finished the half with substantial cash after completing a A$3.9 million share buyback. Management now forecasts full-year 2026 royalties of US$53–56 million, with an additional US$35 million milestone possible from European sales and up to US$50 million more tied to North American targets.
DAYBUE Sales Powered by US Growth and New Format
DAYBUE net sales for the first half of 2026 reached US$226 million, up 25% year-over-year. Market Screener noted the growth was driven by strong US demand and rising adoption of DAYBUE STIX, a simpler formulation. By June 30, 2026, about 40% of all US patients taking DAYBUE had switched to STIX.
Partner Acadia Pharmaceuticals lifted its full-year 2026 net sales guidance to US$480–510 million, signaling confidence in continued momentum. TipRanks reported Acadia is forecasting US$700 million in annual sales by 2028, underscoring belief in the drug's long-term market potential.
European Approval Opens New Revenue Stream for Neuren
The European Commission granted DAYBUE marketing authorization across all 27 EU member states plus Iceland, Liechtenstein, and Norway on August 24, 2026. Germany is set to launch in early Q4 2026, marking Neuren's entry into one of the world's largest pharma markets.
Market Screener highlighted a potential US$35 million milestone payment to Neuren upon the first commercial DAYBUE sale in Europe. This milestone, combined with US sales targets that could unlock US$50 million more, positions the company for significant royalty upside through 2027 and 2028.
NNZ-2591 Pipeline Advances in Rare Neurological Disorders
Neuren is advancing NNZ-2591 (ercanetide), its experimental treatment for rare brain disorders. The Koala Phase 3 study in Pitt Hopkins syndrome has enrolled 15 sites across the US and Canada, with eight sites activated for the open-label extension phase.
Market Screener reported the company is pursuing a Type B End of Phase 2 meeting with the US FDA for Pitt Hopkins syndrome, a key step toward potentially accelerated development. Progress here would help fund the pipeline while DAYBUE royalties flow to shareholders.
Dividend Policy Anchored to Royalty Income Pool
Neuren's semi-annual dividend policy targets a payout of 70% to 100% of after-tax royalty income, minus corporate costs. Kalkine Media explained the inaugural 15-cent fully franked dividend reflects an Available Pool equal to 90% of H1 royalty earnings, with ex-dividend date September 15, 2026.
The policy allows the company to return capital to shareholders while preserving cash for NNZ-2591 development and milestone payments. TipRanks noted this approach aligns investor interests with the company's dual strategy of harvesting DAYBUE royalties and advancing its own pipeline.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
19
Reach
29
Topics
A
AnonymousAuthor
